Changing the Standard of Care for Underserved Patients

Welcome to Theris Medical, TauTona Group’s new biopharmaceutical company focused on developing solutions for the treatment of skin ulcers in patients with sickle cell disease.

Today, there is no FDA-approved treatment on the market for sickle cell disease ulcers, which is an extremely painful condition and often recurrent. In the USA alone, the incidence of sickle cell disease ulcers is 14,000.

Theris aims to change this with a novel medical application using DFO, a drug Sickle Cell Disease patients are already using with a good safety profile. We have received Orphan Drug Designation by the FDA.

Clinical Trials

We will be starting clinical trials in Q4 2019. For more information regarding the trials and patient eligibility please contact us at:

dscout@tautonagroup.com

Participate in Clinical Research